# Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels

> **NCT00083928** · PHASE2 · COMPLETED · sponsor: **Ångstrom Pharmaceuticals** · enrollment: 60 (estimated)

## Conditions studied

- Ovarian Cancer
- Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** Å6 subcutaneous injection

## Key facts

- **NCT ID:** NCT00083928
- **Lead sponsor:** Ångstrom Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2006-02
- **Final completion:** 2006-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2013-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083928, "Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00083928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*